Home > Insider Trading > Filing (0001181431-13-041152)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1302573	Oncomed Pharmaceuticals Inc	OMED	Pharmaceutical Preparations (2834)	383572512

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1297000	Denise Pollard-Knight	C/O Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-07-23	2,063,983	$0.00	2,063,983	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2013-07-23	58,824	$17.00	2,122,807	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B-1 Preferred Stock	Disposition	2013-07-23	2,063,983	$0.00	2,063,983	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

Each share of Series B-1 Preferred Stock automatically converted on a one-to-one basis into Common Stock immediately prior to the consummation of the Issuer's initial public offering on July 23, 2013.
The shares are owned by Phase4 Ventures III LP ("Phase4"). Phase4 Ventures III GP LP, ("Phase4 GPLP"), is the general partner of Phase4 and the reporting person is a limited partner in Phase4 GPLP. As such, the reporting person may be deemed to share voting and dispositive power over the reported securities. The reporting person disclaims beneficial ownership of the reported securities held by Phase4 except to the extent of her pecuniary interest therein.
The securities are immediately convertible.
The expiration date is not relevant to the conversion of these securities.